These considerations make it difficult to suggest an postoperative strategy including radiation therapy for the patients included in the developed question, and suggests a case-by-case evaluation by the clinician based on the biological phenotype (i.e. luminal-like type vs triple negative, HER2-positive) and specific clinical characteristics (tumor extension at diagnosis and residual disease after preoperative treatment). The gene discussed is ERBB2; the disease is neoplasm.